Hydrocortisone Butyrate

Summary

Hydrocortisone Butyrate (CHEMBL1683) is an approved small-molecule dermatologic drug (ATC D07AB02); indicated across 4 conditions including atopic eczema and skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AB02
• Indications: 4 conditions
• Clinical trials: 6
• Chemistry: 432.5 Da · C25H36O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1683
Name	Hydrocortisone Butyrate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	26133
ChEBI	CHEBI:31674
ATC	D07AB02
Molecular formula	C25H36O6
Molecular weight	432.5
InChIKey	BMCQMVFGOVHVNG-TUFAYURCSA-N

SMILES: CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CO

IUPAC name: [(8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] butanoate

ChEBI definition: Cortisol esterified with butyric acid at the 17-hydroxy group.

Pharmacological roles (ChEBI): dermatologic drug, drug allergen.

Also known as: Hydrocortisone butyrate, Locoid, Locoid c, Locoid crelo, Locoid lipocream, NSC-758433, SID11533027, HYDROCORTISONE BUTYRATE, SID56422894, SID144204950, SID170465456, hydrocortisone-butyrate

Patent coverage: 3,785 distinct patent families (14,031 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Mineralocorticoid receptor, Glucocorticoid receptor, Progesterone receptor, Androgen receptor, Cruzipain.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C2	8.53	EC50	2.94	nM	CHEMBL_ACT_27195986
NR3C1	8.1	AC50	8	nM	CHEMBL_ACT_25175707
PGR	7.38	AC50	42	nM	CHEMBL_ACT_25222921
P15207	5.37	AC50	4253	nM	CHEMBL_ACT_25187361

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atopic eczema	4	MONDO:0004980	EFO:0000274
skin disorder	4	MONDO:0005093	EFO:0000701
seborrheic dermatitis	4	MONDO:0006608	EFO:1000764
psoriasis	1	MONDO:0005083	EFO:1001494

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	2
PHASE1	2
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02959580	PHASE4	UNKNOWN	Medical and Surgical Treatment for Idiopathic Granulomatous Mastitis
NCT03766997	PHASE4	UNKNOWN	Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)
NCT03676933	PHASE2	COMPLETED	Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis
NCT02973776	PHASE1	COMPLETED	Vasoconstriction Trial With LEO 90100 Aerosol Foam
NCT03758365	PHASE1	COMPLETED	Evaluation of the Vasoconstriction Properties of MC2-01 Cream
NCT02153762	Not specified	COMPLETED	Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).